Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 268, 10.1111/j.1469-0691.2011.03570.x
Durante-Mangoni, 2011, Global spread of multi-drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance, Future Microbiol, 6, 407, 10.2217/fmb.11.23
Peleg, 2008, Acinetobacter baumannii: emergence of a successful pathogen, Clin Microbiol Rev, 21, 538, 10.1128/CMR.00058-07
Sunenshine, 2007, Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization, Emerg Infect Dis, 13, 97, 10.3201/eid1301.060716
Karageorgopoulos, 2008, Current control and treatment of multidrug-resistant Acinetobacter baumannii infections, Lancet Infect Dis, 8, 751, 10.1016/S1473-3099(08)70279-2
Higgins, 2010, Global spread of carbapenem-resistant Acinetobacter baumannii, J Antimicrob Chemother, 65, 233, 10.1093/jac/dkp428
Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732
Reina, 2005, Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study, Intensive Care Med, 31, 1058, 10.1007/s00134-005-2691-4
Markou, 2003, Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients, Crit Care, 7, R78, 10.1186/cc2358
Li, 2006, Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections, Lancet Infect Dis, 6, 589, 10.1016/S1473-3099(06)70580-1
Falagas, 2010, Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients, Int J Antimicrob Agents, 35, 194, 10.1016/j.ijantimicag.2009.10.005
Petrosillo, 2008, Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies, Clin Microbiol Infect, 14, 816, 10.1111/j.1469-0691.2008.02061.x
Imberti, 2010, Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration, Chest, 138, 1333, 10.1378/chest.10-0463
Falagas, 2006, Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies, Crit Care, 10, R48, 10.1186/cc4869
Giamarellos-Bourboulis, 2001, Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii, Diagn Microbiol Infect Dis, 40, 117, 10.1016/S0732-8893(01)00258-9
Tripodi, 2007, Comparative activities of colistin, rifampicin, imipenem, sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases, Int J Antimicrob Agents, 30, 537, 10.1016/j.ijantimicag.2007.07.007
Li, 2007, Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains, Clin Infect Dis, 45, 594, 10.1086/520658
Pantopoulou, 2007, Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin, Int J Antimicrob Agents, 29, 51, 10.1016/j.ijantimicag.2006.09.009
Pachon-Ibanez, 2010, Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 54, 1165, 10.1128/AAC.00367-09
Petrosillo, 2005, Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events, Clin Microbiol Infect, 11, 682, 10.1111/j.1469-0691.2005.01198.x
Motaouakkil, 2006, Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii, J Infect, 53, 274, 10.1016/j.jinf.2005.11.019
Bassetti, 2008, Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections, J Antimicrob Chemother, 61, 417, 10.1093/jac/dkm509
Li, 2005, Evaluation of colistin as an agent against multi-resistant gram-negative bacteria, Int J Antimicrob Agents, 25, 11, 10.1016/j.ijantimicag.2004.10.001
Savage, 2001, Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria, Ann Med, 33, 167, 10.3109/07853890109002073
Le Gall, 1993, A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study, JAMA, 270, 2957, 10.1001/jama.1993.03510240069035
Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8
American Thoracic Society, 2005, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST
Mermel, 2001, Guidelines for the management of intravascular catheter-related infections, Infect Control Hosp Epidemiol, 22, 222, 10.1086/501893
Solomkin, 2003, Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections, Clin Infect Dis, 37, 997, 10.1086/378702
Pogue, 2011, Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system, Clin Infect Dis, 53, 879, 10.1093/cid/cir611
DeRyke, 2010, Colistin dosing and nephrotoxicity in a large community teaching hospital, Antimicrob Agents Chemother, 54, 4503, 10.1128/AAC.01707-09
Giannouli, 2012, Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy, Int J Antimicrob Agents, 39, 58, 10.1016/j.ijantimicag.2011.09.016
Clinical and Laboratory Standards Institute, 2008, Performance standards for antimicrobial susceptibility testing: 18th informational supplement
Bonnet, Comitè de l'antibiogramme de la Societe Francaise de Microbiologie
Zarrilli, 2007, Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy, Clin Microbiol Infect, 13, 481, 10.1111/j.1469-0691.2006.01675.x
Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X
Paterson, 2010, How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection, Clin Infect Dis, 51, 1245, 10.1086/657243
Markou, 2008, Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study, Clin Ther, 30, 143, 10.1016/j.clinthera.2008.01.015
Dalfino, 2012, High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study, Clin Infect Dis, 54, 1720, 10.1093/cid/cis286
Couet, 2012, Colistin pharmacokinetics: the fog is lifting, Clin Microbiol Infect, 18, 30, 10.1111/j.1469-0691.2011.03667.x
Falagas, 2005, Nephrotoxicity of intravenous colistin: a prospective evaluation, Int J Antimicrob Agents, 26, 504, 10.1016/j.ijantimicag.2005.09.004